Last updated on November 2019

Direct Acting Antiviral-Post Authorization Safety Study


Brief description of study

This is an independent optional sub-study parallel to TARGET-HCC (NCT02954094). The purpose of Direct-Acting Antiviral-Post Authorization Safety Study (DAA-PASS) is to investigate the impact of exposure to direct-acting antivirals (DAAs) on early recurrence of hepatocellular carcinoma (HCC) in hepatitis C virus (HCV)-infected patients following successful HCC treatment interventions.

Clinical Study Identifier: NCT03707080

Find a site near you

Start Over